No Data
No Data
Bio-Thera Solutions, Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE, An Approved Biosimilar Referencing Tocilizumab In Arthritis Research & Therapy
Bio-Thera Solutions 2024 Semi-Annual Report
Bio-Thera Solutions 2024 Semi-Annual Report Summary
August 23rd A-share Lightning Rod | CMST Development: Shareholder CLH 12 (HK) Limited intends to reduce its shareholding by no more than 3%; Bio-Thera Solutions: Net loss of 0.237 billion yuan in the first half of the year.
CMST Development shareholder CLH 12 (HK) Limited plans to reduce its shareholding by no more than 3%; Guodian Nanjing Automation expressed its intention to sell no more than 28.4198 million shares of CSSC Science & Technology held; 34.7 million shares of CSSC Science & Technology's restricted shares will be lifted on August 23; Shanghai New Power Automotive Technology reported a net loss of 689 million yuan in the first half of the year; bio-thera solutions reported a net loss of 237 million yuan in the first half of the year.
Bio-Thera Solutions' Cancer Drug Gets EU Marketing Approval
Express News | European Medicines Agency (EMA) Approves Bio-Thera Solutions' Bat1706 (Avzivi®, Bevacizumab), a Biosimilar Referencing Avastin®
No Data
No Data